Avanos Medical, Inc. Reports Preliminary Fourth Quarter and Full-Year 2023 Financial Results; Revises Preliminary 2024 Revenue Outlook
ALPHARETTA, Ga., Jan. 4, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported selected, unaudited preliminary financial results for the fourth quarter and full-year ended December 31, 2023 and revised its preliminary revenue outlook for 2024.
- ALPHARETTA, Ga., Jan. 4, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported selected, unaudited preliminary financial results for the fourth quarter and full-year ended December 31, 2023 and revised its preliminary revenue outlook for 2024.
- The Company estimates that net sales for the HA product line will be slightly above $10 million for the fourth quarter of 2023, which is approximately $4 million lower than anticipated.
- The Company will provide additional information regarding its outlook for 2024 on the conference call it will host to discuss its financial results for the quarter and year ended December 31, 2023, which is currently scheduled for February 20, 2024.
- The Company does not intend to update such financial information prior to release of its financial statement information for the quarter and year ended December 31, 2023, which is currently scheduled for February 20, 2024.